The Australian Competition & Consumer Commission announced yesterday that it has approved the merger of generic drugs companies Arrow and Apotex.
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Researchers from three London universities and the Francis Crick Institute have joined together to form a hub for cancer biotherapeutics research and treatment, made possible by a £14 million investment from charity Cancer Research UK.
The US Court of Appeals for the Federal Circuit yesterday overturned a Patent Trial and Appeal Board decision that had said chemical company DuPont hadn’t proved that a patent was invalid.
Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million.
A former GSK scientist has pleaded guilty to charges that he conspired to steal trade secrets to benefit a China-based company that he helped establish, according to the US Department of Justice.
The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.